BiotechTube

Famitinib

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intrahepatic Cholangiocarcinoma

Conditions

Intrahepatic Cholangiocarcinoma

Trial Timeline

Aug 10, 2020 → Feb 10, 2022

NCT ID
NCT04479904

About Famitinib

Famitinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Intrahepatic Cholangiocarcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04479904. Target conditions include Intrahepatic Cholangiocarcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (6)

NCT IDPhaseStatus
NCT05473468Phase 1UNKNOWN
NCT04479904Phase 2Withdrawn
NCT01762293Phase 2Completed
NCT02336724Phase 2UNKNOWN
NCT01994213Phase 2Terminated
NCT01392235Phase 2Completed

Competing Products

20 competing products in Intrahepatic Cholangiocarcinoma

See all competitors
ProductCompanyStageHype Score
ApatinibJiangsu Hengrui MedicinePhase 2
52
Apatinib and Adebrelimab in Combination With chemotherapyJiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + ApatinibJiangsu Hengrui MedicinePhase 2
52
Durvalumab + SNDX-6352AstraZenecaPhase 2
52
Durvalumab + TremelimumabAstraZenecaPhase 2
52
Pemigatinib + DurvalumabAstraZenecaPhase 2
52
Durvalumab + Gemcitabine + CisplatinAstraZenecaPhase 2
52
PemigatinibIncytePhase 2
49
A4250 (odevixibat)IpsenPhase 3
74
OdevixibatIpsenPre-clinical
20
CGT4859Cogent BiosciencesPhase 1/2
38
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 3
74
MaralixibatMirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 2
49
Volixibat + PlaceboMirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 3
74
Maralixibat + PlaceboMirum PharmaceuticalsPhase 3
74
HMPL-453 + RabeprazoleHUTCHMEDPhase 1
28

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85